A Safety Study of Brentuximab Vedotin in Participants With HIV
Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This study will test brentuximab vedotin to see if it is safe for people with human
immunodeficiency virus (HIV) who have low CD4+ and have received antiretroviral therapy (ART)
treatment. It will also see if brentuximab vedotin raises CD4+ counts. It will study the side
effects of this drug as well. A side effect is anything a drug does to the body besides
treating the disease.
In this study participants will be assigned randomly to a group. Participants will get either
brentuximab vedotin or placebo. A placebo looks like the drug but does not contain any
medicine in it. All participants will keep getting ART during the study.